Dupilumab Benefits Esophageal Feature Scores in Children with EoE
At week 52 of the Phase 3 EoE KIDS trial, higher exposure dupilumab significantly improved the endoscopic reference score in children with EoE.
Stay updated with breaking news from Endoscopic Reference Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
At week 52 of the Phase 3 EoE KIDS trial, higher exposure dupilumab significantly improved the endoscopic reference score in children with EoE.
Although delayed diagnosis of EoE presents considerable risk to those with this chronic inflammatory disease, novel treatments are providing hope that a new era is on the horizon.
Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.
Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.
Regular follow-up can reduce the risk of recurrence, esophageal remodeling, fibrosis, and stricture.